If you have been reading about LC-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
=== Diagnostics === As anti-angiogenic cancer therapies have achieved widespread use, there has been increased interest in non-invasive monitoring of angiogenesis. One of the most extensively examined targets of angiogenesis is integrin αVβ3. Radiolabeled peptides containing RGD show high affinity and selectivity for integrin αVβ3 and are being investigated as tools to monitor treatment response of tumors via PET imaging. These include 18F-Galacto-RGD, 18F-Fluciclatide-RGD, 18F-RGD-K5, 68Ga-NOTA-RGD, 68Ga-NOTA-PRGD2, 18F-Alfatide, 18F-Alfatide II, and 18F-FPPRGD2. In a meta-analysis of studies using PET/CT in patients with cancer, it was shown that this diagnostic method may be very useful for detecting malignancies and predicting short-term outcomes, although larger-scale studies are needed.
Heavy experimental and avant-garde acts like the Dillinger Escape Plan, Neurosis, Zeni Geva, Ancestors, and Oranssi Pazuzu all cite King Crimson's influence. Other artists affected by King Crimson include video game composer Nobuo Uematsu, noise music artist Masami Akita of Merzbow, jazz guitarist Dennis Rea of Land, folktronica exponent Juana Molina, hip hop producer RJD2, hip hop and soul composer Adrian Younge, film director Hal Hartley, and folk-pop singer Ian Kelly. Golden Wind, the fifth part of the Japanese manga and anime franchise JoJo's Bizarre Adventure, has its main antagonist Diavolo possess a Stand known as King Crimson. Stephen King's The Dark Tower also has its main antagonist, the Crimson King, named after the band.
Like the world, the EU's greatest task is to replace fossil fuels with clean energy as fast as technology allows since protection of "life", and "improvement of the quality of the environment" are fundamental rights, and the highest policy goals of the EU. In international law, there is also 'the inherent right of all peoples to enjoy and utilize fully and freely their natural wealth and resources' such as clean air, and the right to 'the benefits of scientific progress', such as clean energy. The EU's overall target is to reduce toxic greenhouse gas emissions by 50–55% by 2030, and be carbon neutral or negative by 2050, and 32% renewable energy by 2030, though a 45% target by 2030 was proposed by the commission and backed by Parliament in 2022. Since the 2022 Russian invasion of Ukraine it aims to eliminate Russian fossil fuel imports as fast as possible. However laws such as the Hydrocarbons Directive 1994 still enable gas and oil extraction. It requires that licences are awarded based on technical and financial capability, methods, price, and previous conduct, that applicants are treated equally by objective and non-discriminatory criteria, and advertisements for tenders must be public. It has not yet required that existing licensees pay for the pollution and climate damage they have caused, nor sought to end extraction of gas and oil.
== Disorders == Hyperactivity of theca cells causes hyperandrogenism, and hypoactivity leads to a lack of estrogen. Granulosa cell tumors, while rare (less than 5% of ovarian cancers), may occur in both granulosa cells and theca cells. Thecomas are benign proliferations of theca cells that may present with hormonal dysfunction. Dysfunction in theca cells is one of the leading cause of endocrine-based infertility, as either hyperactivity or hypoactivity of the theca cells can lead to fertility problems.
=== Cardiovascular disease === Adult exposure to PAHs has been linked to cardiovascular disease. PAHs are among the complex suite of contaminants in tobacco smoke and particulate air pollution and may contribute to cardiovascular disease resulting from such exposures. In laboratory experiments, animals exposed to certain PAHs have shown increased development of plaques (atherogenesis) within arteries. Potential mechanisms for the pathogenesis and development of atherosclerotic plaques may be similar to the mechanisms involved in the carcinogenic and mutagenic properties of PAHs. A leading hypothesis is that PAHs may activate the cytochrome enzyme CYP1B1 in vascular smooth muscle cells. This enzyme then metabolically processes the PAHs to quinone metabolites that bind to DNA in reactive adducts that remove purine bases. The resulting mutations may contribute to unregulated growth of vascular smooth muscle cells or to their migration to the inside of the artery, which are steps in plaque formation. These quinone metabolites also generate reactive oxygen species that may alter the activity of genes that affect plaque formation. Oxidative stress following PAH exposure could also result in cardiovascular disease by causing inflammation, which has been recognized as an important factor in the development of atherosclerosis and cardiovascular disease.
Sources: en.wikipedia.org
In archaeology, the term in situ has been used variably to describe artifacts or features found undisturbed since deposition; however, its definition remains contested. Scholars distinguish between a broad usage, referring to materials recovered through controlled excavation, and a stricter usage applied only to those discovered in undisturbed depositional settings. Between these poles lies a continuum of depositional scenarios, from sealed habitation floors to slope or fluvial deposits, meaning that whether an object is in situ depends on site-specific formation processes and the degree to which stratigraphic—as well as spatial—relationships can be reconstructed. Recording the exact spatial coordinates, stratigraphic position, and surrounding matrix of depositional materials is necessary for understanding past human activities and historical processes. While artifacts are often removed for analysis, certain archaeological features—such as hearths, postholes, and architectural foundations—have to be thoroughly documented in place to preserve their contextual information during excavation. This documentation relies on various methods, including detailed field notes, scaled technical drawings, cartographic representation, and high-resolution photographic records. Current archaeological practice incorporates advanced digital technologies, including 3D laser scanning, photogrammetry, unmanned aerial vehicles, and Geographic Information Systems (GIS), to capture complex spatial relationships.
=== 1.4a === DisplayPort version 1.4a was published in April 2018. VESA made no official press release for this version. It updated DisplayPort's Display Stream Compression implementation from DSC 1.2 to 1.2a.
=== Other uses === Phenobarbital is useful for insomnia and anxiety. Phenobarbital is occasionally prescribed in low doses to aid in the conjugation of bilirubin in people with Crigler–Najjar syndrome, type II, or in people with Gilbert's syndrome. In infants suspected of neonatal biliary atresia, phenobarbital is used in preparation for a 99mTc-IDA hepatobiliary (HIDA; hepatobiliary 99mTc-iminodiacetic acid) study that differentiates atresia from hepatitis or cholestasis. In massive doses, phenobarbital is prescribed to terminally ill people to allow them to end their life through physician-assisted suicide.
== Sources == Samuel W. Mitcham (2007). German Order of Battle. Volume Two: 291st–999th Infantry Divisions, Named Infantry Divisions, and Special Divisions in WWII. Stackpole Books. ISBN 978-0-8117-3437-0, p. 148–149. Georg Tessin: Verbände und Truppen der deutschen Wehrmacht und Waffen-SS im Zweiten Weltkrieg 1939–1945. Volume 11. Die Landstreitkräfte 501–630. Biblio-Verlag, Bissendorf 1975, ISBN 3-7648-1181-1, p. 128.
He was involved in the founding of the Australian National University in Canberra and the establishment of its John Curtin School of Medical Research, and he served as chancellor of the Australian National University from 1965 until his death in 1968. He was elected a fellow of the Royal Society in 1941, and as its president from 1960 to 1965, he oversaw its move to new accommodations at Carlton House Terrace and the establishment of links with European organisations. In 1962, he became provost of The Queen's College, Oxford. Florey's discoveries are estimated to have saved over 80 million lives, and he is regarded by the Australian scientific and medical community as one of its greatest figures. Australian prime minister Sir Robert Menzies said, "In terms of world well-being, Florey was the most important man ever born in Australia."
Sources: en.wikipedia.org
Another use for affinity chromatography is the purification of specific proteins using a gel matrix that is unique to a specific protein. For example, the purification of E. coli β-galactosidase is accomplished by affinity chromatography using p-aminobenyl-1-thio-β-D-galactopyranosyl agarose as the affinity matrix. p-aminobenyl-1-thio-β-D-galactopyranosyl agarose is used as the affinity matrix because it contains a galactopyranosyl group, which serves as a good substrate analog for E. coli β-Galactosidase. This property allows the enzyme to bind to the stationary phase of the affinity matrix and β-Galactosidase is eluted by adding increasing concentrations of salt to the column. Alkaline phosphatase from E. coli can be purified using a DEAE-Cellulose matrix. A. phosphatase has a slight negative charge, allowing it to weakly bind to the positively charged amine groups in the matrix. The enzyme can then be eluted out by adding buffer with higher salt concentrations.
=== Nuclear weapons === Neptunium is fissionable, and could theoretically be used as fuel in a fast-neutron reactor or a nuclear weapon, with a critical mass of around 60 kilograms. In 1992, the U.S. Department of Energy declassified the statement that neptunium-237 "can be used for a nuclear explosive device". It is not believed that an actual weapon has ever been constructed using neptunium. As of 2009, the world production of neptunium-237 by commercial power reactors was over 1000 critical masses a year, but to extract the isotope from irradiated fuel elements would be a major industrial undertaking. In September 2002, researchers at the Los Alamos National Laboratory briefly produced the first known nuclear critical mass using a significant fraction of neptunium, in combination with shells of enriched uranium (uranium-235), discovering that the critical mass of a bare sphere of neptunium-237 "ranges from kilogram weights in the high fifties to low sixties", showing that it "is about as good a bomb material as [uranium-235]". The United States Federal government made plans in March 2004 to move America's supply of separated neptunium to a nuclear-waste disposal site in Nevada.
=== Electrode layers and electrolyte === On the macrostructral level (length scale 0.1–5 mm) almost all commercial lithium-ion batteries comprise foil current collectors (aluminium for cathode and copper for anode). Copper is selected for the anode, because lithium does not alloy with it. Aluminum is used for the cathode, because it passivates in LiPF6 electrolytes.
In symbolic terms, he was seen as signifying parliamentary control over the Army. Issues of strategic policy during wartime were managed by the Northern and Southern Departments (the predecessors of today's Foreign Office and Home Office). From 1704 to 1855 the post of Secretary remained occupied by a minister of the second rank (although he was occasionally part of the Cabinet after 1794). Many of his responsibilities were transferred to the Secretary of State for War after the creation of that more senior post in 1794 (though the latter was also responsible for Britain's colonies from 1801, and renamed Secretary of State for War and the Colonies, an arrangement which only ceased with the establishment of the Colonial Office in 1854). From 1824 the British Empire (excepting India, which was administered separately by the East India Company and then the India Office) was divided by the War and Colonial Office into the following administrative departments: North America
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.